•  ()
  •  ()
  • Print this Story
  • Email this Story

Study Finds FDA Program May Be Too Slow For Some Cancer Drugs

Dr. Charles Bennett, A.C. Buehler Professor in Economics and Aging at Northwestern's Feinberg School of Medicine, led the study and discusses it.

text size AAA
July 1, 2009 | by Brendan Cosgrove

Listen Now

CHICAGO --- A new study by researchers at Northwestern University indicates that the Food and Drug Administration’s accelerated approval program, designed to speed up the regulatory process for new drugs used to treat life-threatening diseases, may be too slow for some cancer drugs. Dr. Charles Bennett, A.C. Buehler Professor in Economics and Aging at Northwestern's Feinberg School of Medicine, led the study and discusses it.